MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

ADMA Biologics Inc

Cerrado

SectorSalud

18.51 0.22

Resumen

Variación precio

24h

Actual

Mínimo

18.19

Máximo

18.63

Métricas clave

By Trading Economics

Ingresos

-85M

27M

Ventas

-2.7M

115M

P/B

Media del Sector

21.286

39.564

Margen de beneficio

23.435

Empleados

685

EBITDA

-4.7M

35M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+55.66% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

467M

4.3B

Apertura anterior

18.29

Cierre anterior

18.51

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

174 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

ADMA Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2025, 14:13 UTC

Principales Movimientos del Mercado

ADMA Biologics Shares Hit 52-Week High After FDA Approval

Comparación entre iguales

Cambio de precio

ADMA Biologics Inc Esperado

Precio Objetivo

By TipRanks

55.66% repunte

Estimación a 12 meses

Media 28.75 USD  55.66%

Máximo 35 USD

Mínimo 23 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ADMA Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 23.5406Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

174 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.